Key Data on Combination Immunotherapies in BRAF-Mutated Melanoma with Brain Metastases

Author(s):

Doctors discuss the effectiveness of different treatment combinations for patients with BRAF-mutated metastatic melanoma and brain metastases, highlighting that consideration of patient preferences is essential in making treatment decisions.

EP: 1.The Role of Biomarker Testing in the Management of Metastatic Melanoma

EP: 2.Best Practices for Biomarker Testing in Metastatic Melanoma

EP: 3.Differences Between Community and Academic Settings Regarding Biomarker Testing Practices in Metastatic Melanoma

EP: 4.Treatment Options for Patients With Metastatic Melanoma With a BRAF Mutation

EP: 5.Factors Influencing Treatment Decision-Making In Patients With BRAF-Mutated Metastatic Melanoma

EP: 6.Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma

EP: 7.Common Adverse Effects Seen With BRAF/MEK Inhibitor Therapy in Patients With BRAF-Mutated Metastatic Melanoma

EP: 8.Choosing Between Available Combination BRAF/MEK Inhibitor Options for Patients With BRAF-Mutated Metastatic Melanoma

EP: 9.Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial

EP: 10.Efficacy and Safety of Rechallenge With BRAF/MEK Inhibitors in Patients With BRAF-Mutated Metastatic Melanoma

EP: 11.Treatment Approaches For Patients With BRAF-Mutated Melanoma and Asymptomatic Brain Metastases

EP: 12.Treatment Approaches For Patients With BRAF-Mutated Melanoma and Symptomatic Brain Metastases

Now Viewing